Zuellig Pharma launches diabetes, obesity medicine in Thailand

manilatimes.net

Zuellig Pharma will launch Eli Lilly's Mounjaro®, a medicine for obesity and diabetes, in Thailand by the end of May. This marks a significant advancement in treating both conditions. The medicine, tirzepatide, will be available via Zuellig Pharma, which holds the marketing authorization. It's a once-weekly injection for adults with type 2 diabetes or for weight management, addressing a critical public health concern in Thailand. Obesity and diabetes affect a large portion of the Thai population. Mounjaro® offers a single medication solution, and its launch reflects Zuellig Pharma's commitment to accessible healthcare in the region.


With a significance score of 3.3, this news ranks in the top 9.8% of today's 31263 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Zuellig Pharma launches diabetes, obesity medicine in Thailand | News Minimalist